Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-05-08Actual
Enrollment · participants33Actual
Source updated2023-10-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.